Drug
ruxolitinib
Marketed as JAKAFI XR, OPZELURA, JAKAFI.
Generic name
ruxolitinib
Brand names
JAKAFI XR, OPZELURA, JAKAFI
First FDA approval
2011-11-16
FDA approval history
| FDA ID | Brand | Approval date | Manufacturer |
|---|---|---|---|
| NDA217180 | JAKAFI XR | 2026-05-01 | INCYTE CORP |
| NDA215309 | OPZELURA | 2021-09-21 | INCYTE CORP |
| NDA202192 | JAKAFI | 2011-11-16 | INCYTE CORP |
Manufacturers
INCYTE CORP
Frequently asked questions
When was ruxolitinib FDA approved?
Earliest FDA approval on record: 2011-11-16.
What brand names are sold as ruxolitinib?
JAKAFI XR, OPZELURA, JAKAFI.
Sources
Appeal a ruxolitinib denial
Upload the denial notice. DenialHelp helps verify the reason, organize source-linked evidence, and prepare a treating-clinician-reviewable package. Price and refund terms are shown before payment.
Get started →Contact: hello@denialhelp.com